.jpg)
Kate E. Broderick Ph.D
Merck and Moderna have reported positive Phase 3 data. The vaccine, when tested with an existing immunotherapy, significantly slowed the return of melanoma and its spread to other parts of the body. This is no longer just a small-study proof of concept. It is late-stage clinical validation.
Moderna just released five-year follow-up data from their personalized cancer vaccine program with Merck. The data showed sustained disease management in patients with melanoma. Five years of follow-up. That's the kind of long-term data that changes how you think about what's possible.
I've been in this field long enough to remember when mRNA was considered too unstable to be a therapeutic. I watched that change. What I'm watching now with personalized neoantigen vaccines feels like that same kind of inflection point, except the clinical evidence is arriving faster and the unmet need it's addressing is even greater.
But there's a gap between what the clinical data is showing and the manufacturing reality the field needs to close, and I think it's being underestimated.
The Clinical Case
The combination of neoantigen identification technology, rapid sequencing, and nucleic acid-based vaccine platforms has come together in a way that earlier cancer vaccine attempts simply couldn't access. The results in pancreatic cancer and glioblastoma are the most striking because those are the hardest indications. Twelve-month survival rates around ten percent under standard treatment. Early personalized vaccine trials showing patients alive and well at five and six years post-dosing. Five and six years!
That is why the new melanoma data is so important. The exact magnitude of benefit still needs to be reviewed when the full dataset is presented, but the field now has a late-stage randomized signal in resected melanoma.
If those outcomes hold at scale across a range of solid tumors, the case for subjecting patients to chemotherapy and radiation becomes very difficult to make. I'm not overstating this. I think about a woman on one of the earliest pancreatic cancer vaccine trials, now in her eighties and recently climbed Kilimanjaro. Clinically, she shouldn't be alive. And I think about my mother, who went through chemotherapy, and what that treatment did to her. The hope that the next generation of cancer patients won't have to experience that is what makes this work feel urgent, not routine.
The Manufacturing Constraint
Four to six weeks from tumor biopsy to dosing the patient. That's the biological window you're working inside for personalized cancer vaccines, and it's not negotiable. The vaccine needs to be designed, manufactured, and delivered while the immune context created by the biopsy procedure is still active. If you're using plasmid DNA as the starting material for the RNA template, plasmid fermentation alone can consume most of that window, and that's in ideal conditions. If the bacteria don't cooperate with your sequence, you're outside the window entirely.
Synthetic DNA changes that calculation. Our process at Artis is enzymatic rather than biological, sequence-agnostic, and can go from sequence to starting material in days. In a four-to-six-week window, that matters enormously. It's not a process improvement. It's what makes the program viable at the commercial scale where thousands of patients are being treated simultaneously.
Delivery and the LNP Conversation
The current clinical momentum is strongly with mRNA, and the data justifies that. The ability to encode the neoantigen payload, the speed of manufacture, and the established LNP delivery infrastructure all point in that direction for the near term. DNA as an API has strong arguments, particularly in terms of stability, manufacturing simplicity, and the improvements in nuclear translocation our adapter technology enables. My honest view is that mRNA has the clearest near-term path, but synthetic DNA as the upstream input is what makes the mRNA route commercially viable. The two are inextricably linked.
LNP has proven itself for systemic delivery, and the COVID vaccine experience gave us enormous manufacturing and regulatory learning. But in the tumor microenvironment, the story is more complicated. Immunosuppression, poor vascularization, and the specific cell populations you need to reach create real targeting challenges. There's underinvestment in other delivery modalities, including electroporation for DNA delivery, which has genuine advantages for certain tumor-adjacent applications, and interesting work in polymeric nanoparticles that isn't getting the attention it deserves relative to the LNP conversation.
What Needs to Be True for Commercial Scale
Decentralized or distributed manufacturing is probably necessary. You can't centralize manufacturing for thousands of personalized programs and reliably hit the timing window at commercial volumes. The pandemic preparedness work around distributed supply chains is directly applicable here, which is one of the reasons the two fields are more connected than they might appear.
The people working in clinical science need to have much more active conversations with those working on upstream manufacturing right now, not after the Phase 3 data is in. By then, the production bottleneck will be the thing standing between the science and the patients who need it.
Key Takeaways
The clinical data for personalized cancer vaccines is arriving faster than the manufacturing infrastructure to support it. Here is what that gap means for timelines, starting material, and patient access.
Late-stage validation
Merck and Moderna's Phase 3 INTerpath-001 melanoma study met its recurrence-free survival and distant metastasis-free survival endpoints, marking a late-stage randomized signal for a personalized mRNA neoantigen vaccine paired with Keytruda.
Clinical breakthrough
Early personalized cancer vaccine trials are showing five and six-year survivors in pancreatic cancer and glioblastoma, indications with twelve-month survival rates around ten percent under standard treatment.
Durability signal
Earlier Phase 2b follow-up showed a 49% reduction in risk of recurrence or death and a 62% reduction in risk of distant metastasis or death at roughly three years, setting the context for why the Phase 3 readout matters.
The four-to-six-week window
Four to six weeks from biopsy to dose is a biological imperative, not a guideline. The manufacturing timeline is part of the treatment.
Synthetic DNA as the enabler
Plasmid fermentation is incompatible with the biopsy-to-dose window at commercial scale. Synthetic DNA, which can go from sequence to starting material in days, is what makes personalized cancer vaccines viable at scale.
mRNA and synthetic DNA
mRNA has the clearest near-term clinical path, but synthetic DNA as the upstream IVT template is what makes the mRNA route commercially viable. The two are inextricably linked.
Distributed manufacturing
Decentralized manufacturing is probably necessary at commercial scale. Centralized manufacturing for thousands of simultaneous personalized programs cannot reliably hit the timing window.
Access and equity
Patients in low- and middle-income countries without four-to-six-week turnaround infrastructure will be last in line. Access and manufacturing determine the equity story of this technology.
Frequently Asked Questions
The questions developers bring to us most often about manufacturing personalized cancer vaccines at scale.
What does the current wave of personalized cancer vaccines get right that earlier attempts missed?
What is genuinely new is the clinical data. The results coming out now are real, not theoretical. Pancreatic cancer and glioblastoma are essentially death sentences under standard treatment, and we are seeing patients dosed five or six years ago who are still alive and healthy. The combination of neoantigen identification technology, rapid sequencing, and nucleic acid-based vaccine platforms has come together in a way that earlier attempts simply could not achieve.
Where is the field overestimating itself?
The timeline and manufacturing realism. There is enormous enthusiasm, rightly so, but the speed constraint is severe and not fully solved. You have four to six weeks from tumor biopsy to dosing the patient. That is a biological imperative. The upstream manufacturing infrastructure to do that reliably, at scale, across thousands of patients simultaneously, does not yet exist in the form it needs to. The clinical science is spectacular. The supply chain conversation is behind where it needs to be.
What is the actual production bottleneck for personalized cancer vaccines?
The starting material must be synthesized in days, not weeks. If you are using plasmid DNA as the starting material for the RNA template, you are looking at weeks of lead time at best, potentially months if the bacteria do not cooperate with your sequence. With synthetic DNA, you can go from sequence to starting material in days. When you are working in a four-to-six-week window from biopsy to dose, that compression is not optional. It is what makes the program commercially viable.
What does synthetic DNA's role in personalized cancer vaccines look like specifically?
Synthetic DNA is the IVT template that feeds the mRNA manufacturing process. Our adapter technology allows us to engineer better polymerase binding sites than a plasmid can provide, with meaningfully improved processivity. That matters at commercial scale when you are running thousands of personalized programs simultaneously. The mRNA approach has the strongest near-term clinical data, and synthetic DNA is what makes the mRNA route viable at the turnaround speed personalized cancer vaccines require.
Who benefits first from personalized cancer vaccines, and who gets left behind?
The cancers with the highest mutational burden, melanoma, lung cancer, pancreatic cancer, and glioblastoma, are the most immediate beneficiaries based on current data. Patients most likely to be left behind are those in low- and middle-income countries, where the four-to-six-week turnaround infrastructure does not exist, and immunocompromised patients whose immune biology makes vaccine-driven responses harder to achieve. Access and manufacturing infrastructure will determine the equity story of this technology as much as the science does.
Connect with the Artis BioSolutions team
inquiries@artisbiosolution.com | artisbiosolutions.com
.png)
